Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy
Retrieved on:
Wednesday, July 6, 2022
Kidney failure, ARB, Diagnosis, IgA nephropathy, Patient, ESRD, Polyomaviridae, Research, Dialysis, HIV disease progression rates, GLOBE, Biomarker, COVID-19, BK virus, EGFR, TACI, Union, Disease, Virus, U.S. Securities and Exchange Commission, UPCR, Autoantibody, Chronic kidney disease, Cytokine, Stanford University School of Medicine, Immunoglobulin A, Data analysis, Inflammation, Degenerative disease, Kidney, B cell, Immunoglobulin G, Serum, Security (finance), Raasi, Private Securities Litigation Reform Act, FACP, Standard of care, Glomerular filtration rate, Proteinuria, Nasdaq, Lupus nephritis, BK, Autoimmune disease, Coagulation, Acei, Safety, B-cell activating factor, Therapy, Pharmaceutical industry, Vaccine
This builds on the already compelling disease-modifying dose-dependent activity and well-tolerated safety profile for atacicept.
Key Points:
- This builds on the already compelling disease-modifying dose-dependent activity and well-tolerated safety profile for atacicept.
- We look forward to the results of the ORIGIN trial which will be a first for the field.
- Subjects were randomized 2:2:1:2 to atacicept 150 mg, atacicept 75 mg, atacicept 25 mg, or matching placebo.
- Atacicept showed a dose-dependent effect on key biomarkers and clinical markers in a Phase 2a clinical study.